RemeGen Co., Ltd. (REGMF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

RemeGen Co., Ltd. (REGMF) Healthcare & Pipeline Overview

RemeGen Co., Ltd., a China-based biopharmaceutical company, specializes in biologics for autoimmune, oncology, and ophthalmic diseases, with key products like Telitacicept and Disitamab Vedotin. The company operates in Mainland China and the United States, focusing on unmet medical needs within these therapeutic areas, and has a market capitalization of $6.79B.

What Is the Investment Thesis for REGMF?

RemeGen Co., Ltd. presents a notable research candidate within the biotechnology sector, driven by its focus on innovative biologics and a robust pipeline targeting autoimmune, oncology, and ophthalmic diseases. The company's existing products, Telitacicept and Disitamab Vedotin, provide a foundation for revenue generation. The company's pipeline includes multiple clinical trials, including Phase III trials for RC18 in neuromyelitis optica spectrum disorder and rheumatoid arthritis. With a market capitalization of $6.79B and a profit margin of 21.8%, RemeGen demonstrates financial stability. However, as an OTC stock, REGMF has specific risks, including liquidity and disclosure. The company's success hinges on clinical trial outcomes and regulatory approvals.

Based on FMP financials and quantitative analysis

REGMF Key Highlights

• Market capitalization of $6.79B reflects investor confidence in RemeGen's pipeline and commercialized products.
• Profit margin of 21.8% indicates efficient operations and successful commercialization strategies.
• Gross margin of 100.0% suggests strong pricing power and cost management in product manufacturing.
• Beta of 0.72 indicates lower volatility compared to the overall market, potentially appealing to risk-averse investors.
• The company has 2999 employees, reflecting its operational scale and capacity for research and development.

Who Are REGMF's Competitors?

REGMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are REGMF's Key Strengths?

• Innovative biologics pipeline targeting unmet medical needs.
• Existing revenue streams from Telitacicept and Disitamab Vedotin.
• Strong presence in both Mainland China and the United States.
• Experienced management team with expertise in drug development and commercialization.

What Are REGMF's Weaknesses?

• Reliance on successful clinical trial outcomes and regulatory approvals.
• High R&D costs associated with drug development.
• Competition from established pharmaceutical companies.
• OTC market listing may limit access to institutional investors.

What Could Drive REGMF Stock Higher?

• Phase III clinical trial results for RC18 in neuromyelitis optica spectrum disorder expected in late 2026.
• Regulatory submissions for Disitamab Vedotin in new cancer indications planned for 2027.
• Continued expansion of commercial operations in Mainland China and the United States.
• Advancement of preclinical candidates into Phase I clinical trials throughout 2026.
• Strategic partnerships and collaborations to expand market reach and product development.

What Are the Key Risks for REGMF?

• Clinical trial failures or delays could negatively impact the company's pipeline and revenue prospects.
• Regulatory setbacks or rejection of drug applications could delay or prevent commercialization.
• Competition from established pharmaceutical companies with greater resources and market share.
• Dependence on key personnel and potential loss of talent.
• Fluctuations in currency exchange rates between USD and CNY could impact financial results.

What Are the Growth Opportunities for REGMF?

• Expansion of Telitacicept (RC18) indications: RemeGen has the opportunity to expand the use of Telitacicept beyond systemic lupus erythematosus (SLE) into other autoimmune diseases such as neuromyelitis optica spectrum disorder and rheumatoid arthritis, where it is currently in Phase III clinical trials. Success in these trials and subsequent regulatory approvals could significantly increase the drug's market potential, addressing a market estimated to grow to $64 billion by 2029.
• Commercialization of Disitamab Vedotin (RC48) in multiple cancer types: Disitamab Vedotin is being developed for various cancer indications, offering RemeGen the potential to address a broad oncology market. Positive clinical trial results and regulatory approvals in different cancer types could drive substantial revenue growth. The global oncology market is projected to reach $286.6 billion by 2030, providing a significant opportunity for RemeGen.
• Advancement of pipeline candidates: RemeGen has a robust pipeline of preclinical and clinical-stage drug candidates targeting various diseases. Advancing these candidates through clinical trials and securing regulatory approvals could lead to the introduction of new products and expansion into new therapeutic areas. The company's pipeline includes RC28 for ophthalmic diseases and RC98 for solid tumors, demonstrating a diversified approach.
• Strategic partnerships and collaborations: RemeGen can pursue strategic partnerships and collaborations with other pharmaceutical and biotechnology companies to accelerate the development and commercialization of its products. Collaborations can provide access to new technologies, funding, and market expertise. This approach can help RemeGen expand its global reach and strengthen its competitive position.
• Geographic expansion: RemeGen currently operates in Mainland China and the United States. Expanding into other geographic markets, such as Europe and other parts of Asia, could provide access to new patient populations and revenue streams. This expansion would require navigating different regulatory environments and establishing distribution networks, but it could significantly increase the company's long-term growth potential.

What Opportunities Does REGMF Have?

• Expansion of existing products into new indications.
• Strategic partnerships and collaborations to accelerate development.
• Geographic expansion into new markets.
• Advancements in biotechnology and drug delivery technologies.

What Threats Does REGMF Face?

• Clinical trial failures and regulatory setbacks.
• Patent expirations and generic competition.
• Changes in healthcare regulations and reimbursement policies.
• Economic downturns and market volatility.

What Are REGMF's Competitive Advantages?

• Proprietary biologics: RemeGen's patented drug candidates provide a competitive advantage.
• Clinical pipeline: A diverse pipeline of drugs in various stages of development reduces risk.
• Regulatory expertise: Navigating regulatory pathways in China and the US creates a barrier to entry.
• Manufacturing capabilities: In-house manufacturing ensures control over supply and quality.

What Does REGMF Do?

RemeGen Co., Ltd., founded in 2008 and headquartered in Yantai, China, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative biologics. The company focuses on addressing unmet medical needs in autoimmune, oncology, and ophthalmic diseases. RemeGen's lead product, Telitacicept (RC18), is approved for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease. Another key product is Disitamab Vedotin (RC48), which is being developed for various cancer indications. The company's pipeline includes several other drug candidates in various stages of clinical development, targeting conditions such as neuromyelitis optica spectrum disorder, rheumatoid arthritis, wet age-related macular degeneration, and various solid tumors. RemeGen operates in both Mainland China and the United States, seeking to expand its global reach and impact in the biopharmaceutical industry. With a team of 2999 employees, RemeGen is committed to advancing innovative therapies to improve patient outcomes.

What Products and Services Does REGMF Offer?

• Discovers and develops innovative biologics.
• Focuses on treatments for autoimmune diseases.
• Develops therapies for various types of cancer.
• Creates treatments for ophthalmic diseases.
• Conducts clinical trials to evaluate drug efficacy and safety.
• Seeks regulatory approvals for its drug candidates.
• Commercializes approved drugs in Mainland China and the United States.

How Does REGMF Make Money?

• Develops and patents novel biologic drugs.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA and NMPA.
• Manufactures and commercializes approved drugs, either directly or through partnerships.

What Industry Does REGMF Operate In?

RemeGen operates in the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and stringent regulatory requirements. The market for biologics, particularly in autoimmune and oncology, is experiencing significant growth due to the increasing prevalence of these diseases and advancements in biotechnology. RemeGen's focus on innovative biologics positions it to capitalize on these trends. Competitors include companies developing similar therapies, such as AAVXF (Ascendis Pharma A/S) and GNNSF (Genoscience Pharma).

Who Are REGMF's Key Customers?

• Patients suffering from autoimmune diseases like systemic lupus erythematosus.
• Patients diagnosed with various types of cancer.
• Patients with ophthalmic conditions such as wet age-related macular degeneration.
• Healthcare providers who prescribe RemeGen's drugs.

How RemeGen Co., Ltd. Is Valued

RemeGen Co., Ltd. carries a market capitalization of $6.79B, placing it in the mid-cap category. Relative to its peer group, REGMF's quantitative score of 71/100 is above the peer average of 54/100.

Company Profile

RemeGen Co., Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Yantai, CN. The company is led by CEO Jianmin Fang. REGMF has traded publicly since 2021.

ROE 42%Key Financial Metrics

Return on equity for RemeGen Co., Ltd. stands at 42.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 17.5%, showing how much profit it generates from its asset base. REGMF trades at a trailing price-to-earnings ratio of 49.62, above the Healthcare sector average of ~23x. Its free cash flow yield is 0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.58 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

RemeGen Co., Ltd.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.31 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project RemeGen Co., Ltd. revenue of about $7.46B for fiscal 2026, with EPS near $6.05. The estimate reflects 13 contributing analysts.

REGMF Financials

REGMF Latest News

REGMF Analyst Consensus

REGMF MoonshotScore

RemeGen Co., Ltd. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources